In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2

FB2001 is a drug candidate that targets the main protease of SARS-CoV-2 via covalently binding to cysteine 145. In this study, we evaluated the inhibitory activities of FB2001 against several SARS-CoV-2 variants in vitro and in vivo (in mice), and we also evaluated the histopathological analysis and...

Descripción completa

Detalles Bibliográficos
Autores principales: Shang, Weijuan, Dai, Wenhao, Yao, Cheng, Xu, Ling, Tao, Xiangming, Su, Haixia, Li, Jian, Xie, Xiong, Xu, Yechun, Hu, Min, Xie, Dong, Jiang, Hualiang, Zhang, Leike, Liu, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617675/
https://www.ncbi.nlm.nih.gov/pubmed/36354082
http://dx.doi.org/10.1016/j.antiviral.2022.105450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617675/
https://www.ncbi.nlm.nih.gov/pubmed/36354082
http://dx.doi.org/10.1016/j.antiviral.2022.105450

Ejemplares similares